The Oxytocin/Vasopressin Receptor Family Has at Least Five Members in the Gnathostome Lineage, Including Two Distinct V2 Subtypes
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(1982), 24(4), 329—337 Pineal Response to Lithium1
Indian J. Psychiat. (1982), 24(4), 329—337 PINEAL RESPONSE TO LITHIUM1 S. PARVATHI DEVI* A. VENKOBA RAO> PINEAL FUNCTION AND BEHAVIOUR—A until Crowther demonstrated from his REVIEW autopsy studies that pineal calcification The pineal gland in ma.i is an active had nothing to do with mental derange endocrine gland throughout life (Wurtman ment. et al., 1964 ; Tapp & Huxley, 1972 ; Interest in the pineal gland lay dormant Cardinali, 1974 ; Reiter et al., 1975 ; Reiter, and the gland was relegated to be a ves- 1978). It elaborates several hormones with tigeal organ until the endocrine nature precise rhythmicity. The chronobiological of the gland was suggested following des aspects of the mammalian pineal gland have criptions of pineal tumours associated with been clearly brought out by Reiler (198!) precocious puberty (Kitay, 1954). The defining the circadian rhythms in indole idea of a special relation of pineal gland to metabolism within the pineal of mammals. mind was revived in reports of experiments The two major classes of pineal hormones— with pineal extracts in the treatment of pineal indoles (melatonin, serotonin and schizophrenia (Becker, 1920 ; Eldered et the tryptophols) and the polypeptides are al., 196U; Kitay & Altschule, 1954). The known to influence several physiological isolation and characterisation of the pineal systems including the central nervous system hormone melatonin was a turning point (Cardinali, 1974 and Anton Tay, 1974). in pineal research (Lerner et al., 1958). The association of pineal gland with be Since then the pineal gland has been a haviour and mental illness can be traced to focus of intense scientific enquiry revealing Alexandrian school of thought (Herophilus it to be an endocrine gland capable of c. -
Design and Synthesis of Cyclic Analogs of the Kappa Opioid Receptor Antagonist Arodyn
Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn By © 2018 Solomon Aguta Gisemba Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Dr. Michael Rafferty Dr. Teruna Siahaan Dr. Thomas Tolbert Date Defended: 18 April 2018 The dissertation committee for Solomon Aguta Gisemba certifies that this is the approved version of the following dissertation: Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Date Approved: 10 June 2018 ii Abstract Opioid receptors are important therapeutic targets for mood disorders and pain. Kappa opioid receptor (KOR) antagonists have recently shown potential for treating drug addiction and 1,2,3 4 8 depression. Arodyn (Ac[Phe ,Arg ,D-Ala ]Dyn A(1-11)-NH2), an acetylated dynorphin A (Dyn A) analog, has demonstrated potent and selective KOR antagonism, but can be rapidly metabolized by proteases. Cyclization of arodyn could enhance metabolic stability and potentially stabilize the bioactive conformation to give potent and selective analogs. Accordingly, novel cyclization strategies utilizing ring closing metathesis (RCM) were pursued. However, side reactions involving olefin isomerization of O-allyl groups limited the scope of the RCM reactions, and their use to explore structure-activity relationships of aromatic residues. Here we developed synthetic methodology in a model dipeptide study to facilitate RCM involving Tyr(All) residues. Optimized conditions that included microwave heating and the use of isomerization suppressants were applied to the synthesis of cyclic arodyn analogs. -
Radial Glia Reveal Complex Regulation by the Neuropeptide Secretoneurin
Transcriptomic and proteomic characterizations of goldfish (Carassius auratus) radial glia reveal complex regulation by the neuropeptide secretoneurin Dillon Da Fonte Thesis submitted to the Faculty of Graduate and Postdoctoral Studies University of Ottawa in partial fulfillment of the requirements for the Master of Science degree in biology Department of Biology Faculty of Science University of Ottawa © Dillon Da Fonte, Ottawa, Canada, 2016 Acknowledgements Finishing this thesis has been both a challenging and rewarding experience. This accomplishment would not have been possible without the never-ending support of colleagues, friends, family. First, I would like to express my most sincere gratitude to my supervisor and mentor, Dr. Vance Trudeau. Thank you for the opportunities you have given me, this experience has truly solidified my passion for research. I appreciate our many conversations that were enjoyed over a beer – it was truly a memorable experience. I would also like to thank my M.Sc. advisory committee, Dr. Michael Jonz and Dr. Marc Ekker for your time and insightful comments. A special thank you to Dr. Chris Martynuik who taught me the bioinformatics needed to analyze both transcriptomic and proteomic data and for all your help during my time at the University of Florida. I would like to also acknowledge my funding support from University of Ottawa, NSERC, and the Michael Smith Foreign Study Award for supporting my research stay at the University of Florida. To all current and past members of TeamENDO, thank you for the sense of community you all instilled in the lab. Both inside and outside the lab, I have made memories with all of you that I will cherish forever. -
Design and Synthesis of Functionally Selective Kappa Opioid Receptor Ligands
Design and Synthesis of Functionally Selective Kappa Opioid Receptor Ligands By Stephanie Nicole Johnson Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Masters in Science. Chairperson: Dr. Thomas E. Prisinzano Dr. Apurba Dutta Dr. Jeffrey P. Krise Date Defended: May 2, 2017 The Thesis Committee for Stephanie Nicole Johnson certifies that this is the approved version of the following thesis: Design and Synthesis of Functionally Selective Kappa Opioid Receptor Ligands Chairperson: Dr. Thomas E. Prisinzano Date approved: May 4, 2017 ii Abstract The ability of ligands to differentially regulate the activity of signaling pathways coupled to a receptor potentially enables researchers to optimize therapeutically relevant efficacies, while minimizing activity at pathways that lead to adverse effects. Recent studies have demonstrated the functional selectivity of kappa opioid receptor (KOR) ligands acting at KOR expressed by rat peripheral pain sensing neurons. In addition, KOR signaling leading to antinociception and dysphoria occur via different pathways. Based on this information, it can be hypothesized that a functionally selective KOR agonist would allow researchers to optimize signaling pathways leading to antinociception while simultaneously minimizing activity towards pathways that result in dysphoria. In this study, our goal was to alter the structure of U50,488 such that efficacy was maintained for signaling pathways important for antinociception (inhibition of cAMP accumulation) and minimized for signaling pathways that reduce antinociception. Thus, several compounds based on the U50,488 scaffold were designed, synthesized, and evaluated at KORs. Selected analogues were further evaluated for inhibition of cAMP accumulation, activation of extracellular signal-regulated kinase (ERK), and inhibition of calcitonin gene- related peptide release (CGRP). -
Estrogen Receptor (ER) Expression and Function in the Pregnant Human Myometrium: Estradiol Via Era Activates ERK1/2 Signaling in Term Myometrium
227 Estrogen receptor (ER) expression and function in the pregnant human myometrium: estradiol via ERa activates ERK1/2 signaling in term myometrium Toni Welsh1,2, Matrika Johnson1, Lijuan Yi1, Huiqing Tan1, Roksana Rahman1, Amy Merlino1, Tamas Zakar2,3 and Sam Mesiano1 1Department of Reproductive Biology, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, Ohio 44106, USA 2Mothers and Babies Research Centre, University of Newcastle, Newcastle, New South Wales 2308, Australia 3Department of Obstetrics and Gynaecology, John Hunter Hospital, Newcastle, New South Wales 2305, Australia (Correspondence should be addressed to S Mesiano; Email: [email protected]) Abstract Estrogens are thought to promote labor by increasing inhibition of 26S proteasome activity increased ERa protein the expression of pro-contraction genes in myometrial cells. abundance to detectable levels in term myometrial explants, The specific estrogen receptors ((ERs: ERa and ERb (also however, indicating rapid turnover of ERa protein by known as ESR1 and ESR2)) and G protein-coupled receptor proteasomal processing in the pregnant myometrium. E2 30 (GPR30; also known as G protein-coupled estrogen stimulated rapid extranuclear signaling in myometrial explants, receptor 1)) and signaling pathways that mediate these actions as evidenced by increased extracellularly regulated kinase are not clearly understood. In this study, we identified the ERs (ERK1/2) phosphorylation within 10 min. This effect was expressed in the pregnant human myometrium and determined inhibited by pre-treatment with an ER antagonist, ICI a key extranuclear signaling pathway through which estradiol 182 780, indicating the involvement of ERa. Inhibition of (E2) modulates expression of the gene encoding the oxytocin ERK signaling abrogated the ability of E2 to stimulate OXTR receptor (OXTR), a major pro-contraction protein. -
G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes
Int. J. Mol. Sci. 2014, 15, 1112-1142; doi:10.3390/ijms15011112 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes Benoît T. Roux 1 and Graeme S. Cottrell 2,* 1 Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK; E-Mail: [email protected] 2 Reading School of Pharmacy, University of Reading, Reading RG6 6UB, UK * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-118-378-7027; Fax: +44-118-378-4703. Received: 4 December 2013; in revised form: 20 December 2013 / Accepted: 8 January 2014 / Published: 16 January 2014 Abstract: G protein-coupled receptors (GPCRs) are important cell signaling mediators, involved in essential physiological processes. GPCRs respond to a wide variety of ligands from light to large macromolecules, including hormones and small peptides. Unfortunately, mutations and dysregulation of GPCRs that induce a loss of function or alter expression can lead to disorders that are sometimes lethal. Therefore, the expression, trafficking, signaling and desensitization of GPCRs must be tightly regulated by different cellular systems to prevent disease. Although there is substantial knowledge regarding the mechanisms that regulate the desensitization and down-regulation of GPCRs, less is known about the mechanisms that regulate the trafficking and cell-surface expression of newly synthesized GPCRs. More recently, there is accumulating evidence that suggests certain GPCRs are able to interact with specific proteins that can completely change their fate and function. These interactions add on another level of regulation and flexibility between different tissue/cell-types. -
Analysis of the Indacaterol-Regulated Transcriptome in Human Airway
Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol . -
Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands
bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected]. -
How the Energy Sensor, AMPK, Impact the Testicular Function Pascal Froment, Mélanie Faure, Edith Guibert, Jean-Pierre Brillard
How the energy sensor, AMPK, impact the testicular function Pascal Froment, Mélanie Faure, Edith Guibert, Jean-Pierre Brillard To cite this version: Pascal Froment, Mélanie Faure, Edith Guibert, Jean-Pierre Brillard. How the energy sensor, AMPK, impact the testicular function. 27. Conference of European Comparative Endocrinologists, Aug 2014, Rennes, France. 2014. hal-02742016 HAL Id: hal-02742016 https://hal.inrae.fr/hal-02742016 Submitted on 3 Jun 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Copyright 27th Conference of European Comparative Endocrinologists CECE 2014 25-29 August 2014 Rennes, France 3 27th Conference of European Comparative Endocrinologists Organized with the generous support and help of our sponsors Université de Rennes 1 European Society for Comparative Endocrinology (Grants) European Union INTEREG TC2N Rennes Métropole European Society of Endocrinology (Grants) Institut National de la Recherche Agronomique Société de Neuroendocrinologie (Grants) Institut National de l'Environnement Industriel et des Risques !"#$%$&$'()'*)+,)*+,)'#&*'-.'#."$/ -
Evolution of Neuropeptide Signalling Systems (Doi:10.1242/Jeb.151092) Maurice R
© 2018. Published by The Company of Biologists Ltd | Journal of Experimental Biology (2018) 221, jeb193342. doi:10.1242/jeb.193342 CORRECTION Correction: Evolution of neuropeptide signalling systems (doi:10.1242/jeb.151092) Maurice R. Elphick, Olivier Mirabeau and Dan Larhammar There was an error published in J. Exp. Biol. (2018) 221, jeb151092 (doi:10.1242/jeb.151092). In Fig. 2, panels B and C are identical. The correct figure is below. The authors apologise for any inconvenience this may have caused. Journal of Experimental Biology 1 © 2018. Published by The Company of Biologists Ltd | Journal of Experimental Biology (2018) 221, jeb151092. doi:10.1242/jeb.151092 REVIEW Evolution of neuropeptide signalling systems Maurice R. Elphick1,*,‡, Olivier Mirabeau2,* and Dan Larhammar3,* ABSTRACT molecular to the behavioural level (Burbach, 2011; Schoofs et al., Neuropeptides are a diverse class of neuronal signalling molecules 2017; Taghert and Nitabach, 2012; van den Pol, 2012). that regulate physiological processes and behaviour in animals. Among the first neuropeptides to be chemically identified in However, determining the relationships and evolutionary origins of mammals were the hypothalamic neuropeptides vasopressin and the heterogeneous assemblage of neuropeptides identified in a range oxytocin, which act systemically as hormones (e.g. regulating of phyla has presented a huge challenge for comparative physiologists. diuresis and lactation) and act within the brain to influence social Here, we review revolutionary insights into the evolution of behaviour (Donaldson and Young, 2008; Young et al., 2011). neuropeptide signalling that have been obtained recently through Evidence of the evolutionary antiquity of neuropeptide signalling comparative analysis of genome/transcriptome sequence data and by emerged with the molecular identification of neuropeptides in – ‘deorphanisation’ of neuropeptide receptors. -
1 Advances in Therapeutic Peptides Targeting G Protein-Coupled
Advances in therapeutic peptides targeting G protein-coupled receptors Anthony P. Davenport1Ϯ Conor C.G. Scully2Ϯ, Chris de Graaf2, Alastair J. H. Brown2 and Janet J. Maguire1 1Experimental Medicine and Immunotherapeutics, Addenbrooke’s Hospital, University of Cambridge, CB2 0QQ, UK 2Sosei Heptares, Granta Park, Cambridge, CB21 6DG, UK. Ϯ Contributed equally Correspondence to Anthony P. Davenport email: [email protected] Abstract Dysregulation of peptide-activated pathways causes a range of diseases, fostering the discovery and clinical development of peptide drugs. Many endogenous peptides activate G protein-coupled receptors (GPCRs) — nearly fifty GPCR peptide drugs have been approved to date, most of them for metabolic disease or oncology, and more than 10 potentially first- in-class peptide therapeutics are in the pipeline. The majority of existing peptide therapeutics are agonists, which reflects the currently dominant strategy of modifying the endogenous peptide sequence of ligands for peptide-binding GPCRs. Increasingly, novel strategies are being employed to develop both agonists and antagonists, and both to introduce chemical novelty and improve drug-like properties. Pharmacodynamic improvements are evolving to bias ligands to activate specific downstream signalling pathways in order to optimise efficacy and reduce side effects. In pharmacokinetics, modifications that increase plasma-half life have been revolutionary. Here, we discuss the current status of peptide drugs targeting GPCRs, with a focus on evolving strategies to improve pharmacokinetic and pharmacodynamic properties. Introduction G protein-coupled receptors (GPCRs) mediate a wide range of signalling processes and are targeted by one third of drugs in clinical use1. Although most GPCR-targeting therapeutics are small molecules2, the endogenous ligands for many GPCRs are peptides (comprising 50 or fewer amino acids), which suggests that this class of molecule could be therapeutically useful. -
Osteoblast Regulation Via Ligand-Activated Nuclear Trafficking of the Oxytocin Receptor
Osteoblast regulation via ligand-activated nuclear trafficking of the oxytocin receptor Adriana Di Benedettoa,b, Li Sunc,d, Carlo G. Zambonine, Roberto Tammaa, Beatrice Nicoa, Cosima D. Calvanoe, Graziana Colaiannia, Yaoting Jic,d, Giorgio Morib, Maria Granoa, Ping Luc,d, Silvia Coluccia, Tony Yuenc,d, Maria I. Newf,1, Alberta Zallonea,2, and Mone Zaidic,d,g,1,2 aDepartment of Basic Medical Science, Neurosciences and Sensory Organs, University of Bari Aldo Moro Medical School, Bari 70126, Italy; bDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia 71122, Italy; cMount Sinai Bone Program and dDepartment of Medicine, Mount Sinai School of Medicine, New York, NY 10029; eDepartment of Chemistry, University of Bari Aldo Moro, Bari 70126, Italy; and Departments of fPediatrics and gStructural and Chemical Biology, Mount Sinai School of Medicine, New York, NY 10029 Contributed by Maria I. New, October 8, 2014 (sent for review August 27, 2014); reviewed by Xu Cao, Christopher Huang, and Carlos Isales We report that oxytocin (Oxt) receptors (Oxtrs), on stimulation by bisphosphate 3-kinase (Akt/PI3K) (9, 10). Such mechanisms can the ligand Oxt, translocate into the nucleus of osteoblasts, impli- elicit delayed genomic responses. cating this process in the action of Oxt on osteoblast maturation. After being internalized, GPCRs are either recycled back to Sequential immunocytochemistry of intact cells or isolated nucleo- the plasma membrane to resensitize the cell to ligand action or plasts stripped of the outer nuclear membrane showed progressive transported to lysosomes for degradation. Although G proteins nuclear localization of the Oxtr; this nuclear translocation was con- have been found in the Golgi body, endoplasmic reticulum, and firmed by monitoring the movement of Oxtr–EGFP as well as by cytoskeleton (11–13), GPCRs can localize to the nucleus or nuclear immunogold labeling.